Galmed Pharmaceuticals Ltd. Stock price
Is Galmed Pharmaceuticals Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Galmed Pharmaceuticals Ltd. Stock Analysis
Analyst Opinions
6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:
Analyst Opinions
6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:
Don't miss a Thing! We will send you all news about Galmed Pharmaceuticals Ltd. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galmed Pharmaceuticals Ltd. Stock News
Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
| Head office | Israel |
| CEO | Mr. Baharaff |
| Employees | 5 |
| Founded | 2000 |
| Website | www.galmedpharma.com |


